Emergent BioSolutions reported $-113.5M in EBITDA for its fiscal quarter ending in March of 2023.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 120.06M 19.15M Sep/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amarin USD 12.54M 28.57M Jun/2025
ANI Pharmaceuticals USD 83.3M 11.7M Sep/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Exelixis USD 275.36M 19.96M Sep/2026
Glaxosmithkline GBP 2.93B 154M Sep/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Lonza CHF 1.01B 54M Dec/2025
Merck USD 1.42B 2.97B Jun/2026
Moderna USD -687M 571M Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Pacira USD 50.45M 1.78M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Sanofi EUR 5.79B 2.1B Sep/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
United Therapeutics USD 334.2M 20.8M Sep/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024